Alexander I. Spira MD, PhD, FACP, FASCO, on Metastatic EGFR-Mutated NSCLC: Global Study of Izalontamab Brenitecan
IASLC WCLC 2026
Alexander I. Spira MD, PhD, FACP, FASCO, of Virginia Cancer Specialists and US Oncology, discusses findings from a global phase I study of izalontamab brenitecan (BL-B01D1), an antibody-drug conjugate comprising an EGFR x HER3 bispecific antibody conjugated to a novel topoisomerase 1 inhibitor payload via a stable tetrapeptide-based cleavable linker. In a randomized dose-expansion cohort, the agent demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non–small cell lung cancer (NSCLC) (Abstract OA10.01).
Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center, presents efficacy and safety data from a phase II cohort of the ARROS-1 trial, which included patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who were naive to tyrosine kinase inhibitor (TKI) therapy (Abstract PL03.06).
Alberto A. Chiappori, MD, of Moffitt Cancer Center, discusses findings from a phase I trial looking at the safety and efficacy of LB2102, an autologous CAR-T cell therapy targeting DLL3 and armored with a dominant-negative TGF-beta receptor, in pretreated patients with small cell lung cancer (SCLC) (Abstract OA05.02).
Giannis S. Mountzios, MD, of Henry Dunant Hospital Center, reviews primary results from the phase III EVOKE-03/KEYNOTE D46 trial, which evaluated first-line sacituzumab govitecan in combination with pembrolizumab in patients with metastatic non–small cell lung cancer (NSCLC) and a PD-L1 tumor proportion score of 50% or higher (Abstract PL02.06).
Roy S. Herbst, MD, PhD, of Dartmouth Cancer Center, discusses 8-year overall survival data from the landmark ADAURA trial, which showed the sustained long-term benefit of adjuvant therapy with osimertinib for patients with completely resected, EGFR-mutated stage IB–IIIA non–small cell lung cancer (NSCLC) (Abstract PL03.01).
Ricardo Sales dos Santos, MD, PhD, of the ProPulmão Institute, discusses data from the Third Brazilian Early Lung Cancer Trial (BRELT3). The study found low-dose computed tomography (CT) lung cancer screening using a mobile unit is feasible in socially vulnerable populations in resource-limited settings. Community-based recruitment, particularly through community health workers, improved the inclusion of high-risk and underserved groups, supporting the expansion of organized screening programs to promote equitable access and reduce lung cancer mortality (Abstract MO14.03).
